Testing blood-clone risk to prevent chemotherapy complications
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at a specific genetic/production change in blood-forming cells (“clonal hematopoiesis”) to understand who is more likely to have complications from lymphoma chemotherapy. It may help doctors predict risk and possibly reduce harmful side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a lymphoma diagnosis (such as DLBCL, follicular, Hodgkin, CLL/SLL, or other listed types).
- You are starting your first or second course of chemotherapy for lymphoma (sometimes with rituximab).
- You do not have a known blood cancer of myeloid origin (a “myeloid neoplasm”).
- Your lymphocyte count is not too high (must be 10 × 10^9/L or less).
- Your kidneys and liver function are controlled enough for chemotherapy (not significantly above lab limits).
- You do not have HIV and do not have a current (active) infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a modified chemotherapy “conditioning” plan before an autologous stem cell transplant for people with non-Hodgkin lymphoma. It aims to improve how patients tolerate and recover from the transplant process.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
This trial studies whether a blood test (ctDNA) can help doctors safely reduce chemotherapy for people with advanced Hodgkin lymphoma. If you have stage 3 or 4 Hodgkin lymphoma that hasn't been treated yet and are healthy enough for strong chemo, this study may be an option for you.
This study follows people who may have early, unclear blood count problems or certain genetic/immune patterns that can later lead to bone marrow failure or blood cancers. It may help doctors better understand risks over time and guide earlier care.
This study looks at whether blood tests for tumor DNA (cfDNA) can help guide treatment decisions for people with newly diagnosed DLBCL. It focuses on patients who achieve complete remission after 6 rounds of R-CHOP chemotherapy.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.